Axa
NGM

Axa’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Axa’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,500
Closed -$27.2K – 1174
2023
Q2 		$27.2K Buy
+10,500
New +$37.5K ﹤0.01% 1072
2023
Q1 		– Sell
-113,600
Closed -$570K – 1201
2022
Q4 		$570K Sell
113,600
-292,083
-72% -$1.83M ﹤0.01% 974
2022
Q3 		$5.31M Buy
405,683
+3,240
+0.8% +$49.1K 0.02% 565
2022
Q2 		$5.16M Sell
402,443
-7,825
-2% -$108K 0.02% 575
2022
Q1 		$6.26M Buy
410,268
+4
+0% +$62 0.02% 586
2021
Q4 		$7.27M Buy
410,264
+4,897
+1% +$94K 0.02% 571
2021
Q3 		$8.52M Buy
405,367
+112,926
+39% +$2.49M 0.02% 544
2021
Q2 		$5.77M Buy
+292,441
New +$6.84M 0.02% 667

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa's NGM Position: Q3 2023 in Review

Axa sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 10,500 shares — an estimated $27.2K sold.

Axa first reported a position in NGM in Q2 2021 and held it in 8 quarters. The position peaked at $8.52M in Q3 2021. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

  • Axa reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Axa sold 10,500 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $27.2K.
  • Axa first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
  • Axa's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $8.52M in Q3 2021.
  • 94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Axa's 13F filing for Q3 2023, filed 14 Nov 2023.